Regeneron Pharmaceuticals (REGN) Cost of Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Cost of Revenue history runs 18 years deep, the most recent figure standing at $296.0 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 48.89% year-over-year to $296.0 million in Q1 2026; TTM through Mar 2026 was $990.4 million, a 12.06% decrease from a year earlier, with the FY2025 full-year figure at $959.9 million, down 11.72% from the prior year.
• Cost of Revenue rose to $296.0 million in Q1 2026 per REGN's latest filing, from $137.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $442.7 million in Q4 2024 and bottomed at $137.8 million in Q4 2025.
• The 5-year median for Cost of Revenue is $222.4 million (2024), against an average of $236.8 million.
• Across the five-year window, Cost of Revenue soared 193.6% in 2022 and sank 68.87% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $278.0 million in 2022, then slipped by 6.98% to $258.6 million in 2023, then surged by 71.19% to $442.7 million in 2024, then sank by 68.87% to $137.8 million in 2025, then soared by 114.8% to $296.0 million in 2026.
• Per Business Quant, the three latest REGN Cost of Revenue figures stand at $296.0 million (Q1 2026), $137.8 million (Q4 2025), and $281.0 million (Q3 2025).